| Name | Title | Contact Details |
|---|
Insurance Quantified is a leading underwriting technology provider that arms commercial property and casualty insurance carriers and MGAs with the data and analytics they need to grow their business, improve underwriting profitability and be a preferred partner and employer. Backed by Two Sigma, a pioneer and global leader in the financial sciences, we believe that systematically delivering the right data to the right people at the right time will enable faster coverage decisions, more agile product innovation and significant risk reduction for all participants in the underwriting value chain. On June 20, 2023, Insurance Quantified acquired Groundspeed Analytics, the market leader in ingestion and data solutions to the commercial P&C industry. Together, the united technology capabilities, market success, and committed backing of Two Sigma creates an unparalleled underwriting technology partner for commercial insurers.
Hanon Systems is a global provider of automotive thermal and energy management solutions, based in Daejeon, South Korea. Founded in 1986 as Halla Climate Control Corp. through a joint venture between Ford Motor Co. and Mando Machinery Corporation, the company has grown to serve nearly all major automakers. As of 2025, it operates as a subsidiary of Hankook & Company Group, alongside its other core portfolios in tires and batteries. The company specializes in optimizing vehicle performance and occupant comfort through advanced thermal management technologies. Its product offerings include HVAC systems, thermal management components like compressors and cooling modules, and energy efficiency solutions aimed at reducing emissions and improving air quality. Hanon Systems has expanded its capabilities through strategic acquisitions, enhancing its position in the automotive industry. With over 50 facilities worldwide, the company is committed to providing electrification-ready solutions that support the shift toward sustainable mobility.
GKN Powder Metallurgy is the global leader in powder metal solutions, shaping the future with sustainable metal technologies that drive innovation and performance in the automotive and other industries. With a global manufacturing network comprised of 28 manufacturing facilities and 2 innovation centers across 9 countries, we produce 10 million high precision powder metal components daily and 250,000 tons of atomized metal powder per year. Our portfolio of advanced process technologies includes conventional PM for cost-effective, high-volume production; MIM (Metal Injection Molding) for complex, lightweight parts; powder forging for enhanced durability; aluminum PM for lightweight components; and metal additive manufacturing for innovative designs and scalable production. We provide solutions that enable electrification, including manufacturing custom parts for e-motors, e-drivetrains, magnets, batteries, drive-by-wire, and thermal management systems. Our collaborative approach allows us to develop tailor-made solutions that perfectly match your application and deliver superior performance, efficiency, and reduced weight. Sustainability is at the core of who we are. All our metal powders are made from 100% recyclable scrap metal and are designed with the circular economy in mind. Our dedication to combating climate change, minimizing waste, and upholding the highest social responsibility standards has earned us the EcoVadis Platinum medal - an award for excellence in ESG performance given only to the top 1% of companies globally. At GKN Powder Metallurgy, we are not just about manufacturing; we are about technology that impacts the world. Join us as we continue to lead, innovate, and shape the future of manufacturing.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.